Nagoya University researchers in Japan have found that drug effectiveness, alcohol tolerance, and carbohydrate metabolism ...

A large segment of the CYP2C19 rapid metabolizer subgroup is nonresponder to the PPI treatment, only partial symptom relief in GERD, more frequent unsuccessful eradication therapy and lower ...

Camzyos is an oral, selective allosteric and reversible inhibitor of cardiac myosin. It was approved in April 2022 for the treatment of adults with symptomatic New York Heart Association (NYHA) class ...

The company achieved its first UK commercial sales of the Genedrive® CYP2C19-ID Kit and secured a positive assessment from the Scottish Health Technologies Group, leading to government investment ...

Their products, such as the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, are designed to assist clinicians in making informed decisions about medication use, particularly in ...

In rapid metabolizers of the CYP2C19 isoenzyme, the clearance of omeprazole, lansoprazole and pantoprazole markedly increased compared with that of poor metabolizers, resulting in lower plasma ...